MAOIs Amfetamine

Monoamine oxidase inhibitors (MAOI) are not completely selective for MAO and impair the metabolism of tricyclic antidepressants, of some sympathomimetics, e.g. phenylpropanolamine, amfetamine, of opioid analgesics, especially pethidine, and of mercaptopurine. 

After 5 to 10 days of use furazolidone has MAO-inhibitory activity about equivalent to that of the non-selective MAOIs. The concurrent use of furazolidone with indirectly-acting sympathomimetic amines (amfetamines, phenylpropanolamine, ephedrine, etc.) or with tyramine-rich foods and drinks may be expected to result in a potentially serious rise in blood pressure. However, direct evidence of accidental adverse reactions of this kind does not seem to have been reported. The pressor effects of noradrenaline (norepinephrine) are unchanged by furazolidone. 

MAOIs or RIMAs + Sympathomimetics Amfetamines and related drugs... 

The concurrent use of non-selective MAOIs and amfetamines and related drugs can result in a potentially fatal hypertensive crisis and/or serotonin syndrome. Interactions have been reported for amfetamine, dexamfetamine, metamfetamine, and methylpheni-date. Interactions have also been reported with the illicit drug ecstasy (MDMA, methylenedioxymethamfetamine) when taken with phenelzine or moclobemide. The manufacturers of fenfluramine and dexfenfluramine contraindicated their use with MAOIs. 

---